Skip to main content

Join us on our mission to find the next breakthrough treatment for retinitis pigmentosa.

Learn More

Two million patients worldwide suffer from retinitis pigmentosa (RP), the most common form of Rod‑Cone Dystrophy (RCD), and there is still no treatment available for most patients.

Unlike traditional gene therapies intended for patients whose disease is caused by a specific genetic variant, gene-independent gene therapies are a new class of medicines which holds the potential to provide treatment regardless of the underlying genetic cause.

 

Status & Location

33

The PRODYGY study will recruit a total of 33 patients in the U.S. and will take place at:

OHSU Casey Eye Institute

545 SW Campus Drive, Portland, OR 97239

UPMC Vision Institute

1622 Locust Street, Pittsburgh, PA 15213

Bascom Palmer Eye Institute-University of Miami

900 NW 17th Street Miami, FL 33136

Travel and accommodation will be arranged for study participants and their caregivers through Scout Clinical.

About the Study

PRODYGY is a clinical study evaluating the potential of an investigational drug called SPVN06 for the treatment of retinitis pigmentosa (RP).

Learn More